IBM’s AI Monetization Test Narrows to One Earnings Report

Friday’s 2.28% slide in IBM’s shares, which closed at €252.40, could easily be dismissed as a garden-variety pullback after a strong run. Over the past 30 days the stock has still gained 6.86%, and year-to-date it has edged up 1.51%. But the trigger for the dip — a fresh “Neutral” rating from Susquehanna, a new voice on the stock — exposed how finely balanced the debate over IBM’s AI transformation has become. With the second-quarter earnings report scheduled for July 22 at 5 p.m. Eastern, the company’s story is entering its most critical phase.

Susquehanna set a price target of $303, above the current level, but the mere arrival of a neutral stance two weeks before results was enough to shake a stock that had already extended sharply from its May low. Meanwhile, BofA Securities lifted its target to $330 with a Buy rating, anticipating second-quarter revenue of $18.0 billion and earnings per share of $3.03. Jefferies remains constructive at $320, underpinning a bull case that leans on software pipeline momentum and deep roots in regulated industries. Yet the consensus analyst price target of €257.99 implies only 2.2% upside from Friday’s close — a stark disconnect that says the market isn’t sure which camp is right.

That uncertainty is rooted in two competing narratives about the same company. One holds that IBM is well positioned for the AI era through its infrastructure focus, consulting business, and agent-orchestration tools unveiled at the Think 2026 conference in Boston. The other warns that generative AI is actually eating into IBM’s legacy COBOL modernization revenue, while pressure on software margins and a potential softening of infrastructure demand could offset any gains. Neither story has yet won the argument, and the upcoming numbers are widely seen as the arbiter.

The stock’s chart reflects this standoff. At €252.40, IBM sits 10.53% above its 50-day moving average of €228.35 and 6.48% above the 200-day average of €237.03, keeping the intermediate- and long-term trends intact. But the 52-week high of €292.85, set on June 1, now stands 13.81% above the current price, while the year’s low of €181.32 from May 13 is 39.20% below it — a range that speaks to violent swings unusual for a company of IBM’s size. The 30-day annualized volatility of 43.58% underscores that the market is treating it more like a growth stock than a steady tech bellwether.

Should investors sell immediately? Or is it worth buying IBM?

The RSI of 56.4 sits in neutral territory, leaving room for moves in either direction without signaling extremes. The key support to watch is the 200-day average at €237.03, just 6.48% below; a break below that level before earnings would signal that the bearish narrative is gaining the upper hand. For now, both the 50-day and 100-day averages (the latter at €218.67) sit well below the stock, suggesting the short- to medium-term trend structure remains positive — but barely.

Behind the price action lies a deeper industry problem that IBM is trying to solve. The company’s own CEO study found that only 25% of corporate AI projects deliver the expected returns, and a mere 16% are deployed at enterprise scale. At Think 2026, IBM responded with products aimed at agent orchestration, real-time data, intelligent operations, and digital sovereignty — tools designed to convert pilots into controlled, productive systems. The revamped Bob development platform, now featuring multi-agent capabilities, baked-in cost analysis, and pre-built workflows for legacy system modernization, reflects a shift from generating AI output to validating and governing it. Bobalytics, a new consumption-monitoring tool, extends that logic to help companies track usage and maintain oversight.

The same discipline is being applied to IBM’s core mainframe business. The z17 platform, launched last year, is receiving an update designed to bring AI directly to the most valuable transactions and mission-critical applications. By linking its highest-margin legacy unit with AI governance rather than flashy novelty, IBM is betting that the next market phase will reward control over hype.

But the clock is ticking. With a market capitalization of €242.96 billion, IBM is too large to fly under the radar. The July 22 report will be a referendum on whether the company’s pivot toward AI trust and auditability is translating into measurable software growth — or whether the bears who see a legacy drag are correct. Friday’s slip on a neutral rating may prove to be a minor tremor, but it serves as a warning that two weeks is a long time for a stock this stretched to wait for answers.